Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Certolizumab pegol

Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Arthritis & Rheumatology  |  June 27, 2019

Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Arthritis & Rheumatologyaxial spondyloarthritis (SpA)Certolizumab PegolResearch

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Michele B. Kaufman, PharmD, BCGP  |  May 7, 2019

Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…

Filed under:Biologics/DMARDsDrug Updates Tagged with:breastfeedingCanadaCertolizumab PegolNICEplaque psoriasispregnant womenU.K.

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2019

Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…

Filed under:Drug Updates Tagged with:axial spondyloarthritis (SpA)Certolizumab PegolFDAnon-radiographic axial spondyloarthritisU.S. Food and Drug Administration (FDA)

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2018

In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisCertolizumab PegolixekizumabPsoriasis

EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2018

In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:breast milkbreastfeedingCertolizumab PegolEuropean Medicines Agencypregnancypregnant women

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2017

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Sclerosis Tagged with:Certolizumab Pegoletanerceptplaque psoriasis

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

Filed under:Drug Updates Tagged with:breast milkbreastfeedingCertolizumab Pegolinfantspregnancy

Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  June 29, 2016

A recent study found that certolizumab pegol plus methotrexate is effective in achieving sustained remission and low disease activity in patients with early active RA…

Filed under:Drug Updates Tagged with:Certolizumab Pegolcombination therapyDisease-modifying antirheumatic drugs (DMARDs)Methotrexate

Certolizumab Pegol Effective for Treating Rheumatoid Arthritis

Reuters Staff  |  July 19, 2015

NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:anti-TNF agentCertolizumab PegolMethotrexateRheumatiod arthritis

  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences